{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:04:43Z","timestamp":1788815083968,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.anai.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T05:30:32Z","timestamp":1477287032000},"page":"546-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma"],"prefix":"10.1016","volume":"117","author":[{"given":"Tugba Songul","family":"Tat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"Cilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2016.09.006_bib1","unstructured":"Pocket Guide for Asthma Management and Prevention. Global Initiative for Asthma (GINA) Report 2016. http:\/\/www.ginasthma.org\/2016-pocket-guide-for-asthma-management-and-prevention\/. Accessed June 26, 2016."},{"key":"10.1016\/j.anai.2016.09.006_bib2","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2016.09.006_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma","volume":"59","author":"Ayres","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2016.09.006_bib4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1183\/09031936.02.00016502","article-title":"The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2016.09.006_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02770900500369868","article-title":"Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL)","volume":"42","author":"Luskin","year":"2005","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.anai.2016.09.006_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.anai.2010.09.011","article-title":"Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma","volume":"105","author":"Karpel","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.09.006_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/03007991003771338","article-title":"Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma","volume":"26","author":"Kulus","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.anai.2016.09.006_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jaci.2010.05.035","article-title":"Asthma in the elderly: diagnosis and management","volume":"126","author":"Reed","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(10)61087-2","article-title":"Asthma in older adults","volume":"376","author":"Gibson","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2016.09.006_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1081-1206(10)60907-6","article-title":"Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study","volume":"96","author":"Slavin","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1038\/srep08191","article-title":"Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis","volume":"5","author":"Lai","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.anai.2016.09.006_bib12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2016.09.006_bib13","series-title":"GINA Report","author":"Global Strategy for Asthma Management and Prevention","year":"2016"},{"key":"10.1016\/j.anai.2016.09.006_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pupt.2015.01.006","article-title":"Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address","volume":"31","author":"Caminati","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.anai.2016.09.006_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(07)61092-7","article-title":"The challenge of managing drug interactions in elderly people","volume":"370","author":"Mallet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2016.09.006_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5455\/msm.2016.28.129-132","article-title":"Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies","volume":"28","author":"Zelko","year":"2016","journal-title":"Materia Socio-medica"},{"key":"10.1016\/j.anai.2016.09.006_bib17","series-title":"GINA Report","author":"Asthma, COPD, and Asthma-COPD Overlap Syndrome (ACOS)","year":"2015"},{"key":"10.1016\/j.anai.2016.09.006_bib18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/02770903.2016.1178281","article-title":"Omalizumab treatment in asthma-COPD overlap syndrome","volume":"53","author":"Tat","year":"2016","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.anai.2016.09.006_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.rmr.2015.07.005","article-title":"Severe uncontrolled asthma in patients over 75 years old: treatment with omalizumab","volume":"33","author":"Romand","year":"2016","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.anai.2016.09.006_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.anai.2010.07.007","article-title":"Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma","volume":"105","author":"Korn","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2016.09.006_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2016.09.006_bib22","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616306330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120616306330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:16:41Z","timestamp":1761052601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120616306330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1081120616306330"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2016.09.006","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}